HHS Awards $105 Million to Community Health Centers for Quality Improvement

Aug. 16, 2017
The U.S. Department of Health and Human Services (HHS) has awarded nearly $105 million to 1,333 health centers in all U.S. states, territories and the District of Columbia as an investment in quality improvement.

The U.S. Department of Health and Human Services (HHS) has awarded nearly $105 million to 1,333 health centers in all U.S. states, territories and the District of Columbia as an investment in quality improvement.

Health centers will use these funds to further improve the quality, efficiency, and effectiveness of the health care delivered to the communities they serve, according to HHS.

“Americans deserve a healthcare system that’s affordable, accessible, of the highest quality, with ample choices, driven by world-leading innovations, and responsive to the needs of the individual patient,” HHS Secretary Price said in a statement. “Supporting health centers across the country helps to achieve that mission.”

Health centers are receiving these funds to continue improving their services based upon high levels of performance in one or more of the following categories: Improving Quality of Care, Increasing Access to Care, Enhancing Delivery of High Value Health Care, Addressing Health Disparities, and Achieving Patient-Centered Medical Home (PCMH) Recognition.

“Today’s awards will help health centers to provide their communities with high quality, affordable primary care,” HRSA Administrator Dr. George Sigounas said. “Quality care remains a critical trait of the Health Center Program, especially because health centers are treating more patients than ever before.”

HRSA also released new data compiled from health centers through its Uniform Data System (UDS) reporting, providing an update on the primary care services being provided to patients. In 2016, nearly 26 million people (approximately 1 in 12 U.S. residents) relied on a HRSA-funded health center for affordable, accessible primary health care including: one in three people living in poverty; one in ten U.S. children 17 years or younger; one in six U.S. rural residents; and more than 330,000 U.S. veterans.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1